Mölndal, Sweden

Roine Inge Olsson

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2016-2019

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Roine Inge Olsson: Innovator in Immune-Related Disease Treatment

Introduction

Roine Inge Olsson is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating immune-related diseases. With a total of 3 patents to his name, Olsson's work is recognized for its potential impact on medical science.

Latest Patents

Olsson's latest patents include innovative compounds that serve as inhibitors of retinoic acid-related orphan receptor gamma (ROR gamma). One of his notable inventions is focused on indazole and indole derivatives, which are designed to treat immune-related diseases. The compounds provided in this patent are characterized by specific formulas, wherein various components are defined to enhance their efficacy as RORγt antagonists. Another patent involves indolyl-containing RORγt inhibitors, which are also aimed at treating diseases mediated by RORγt.

Career Highlights

Roine Inge Olsson is currently associated with Orca Pharmaceuticals Limited, where he continues to advance his research and development efforts. His work is pivotal in the pharmaceutical industry, particularly in the realm of autoimmune and inflammatory conditions.

Collaborations

Olsson has collaborated with notable professionals in his field, including Clive McCarthy and Naomi Went. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Roine Inge Olsson stands out as an influential inventor in the pharmaceutical sector, with a focus on innovative treatments for immune-related diseases. His contributions through patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…